BLT 0.00% 2.6¢ benitec biopharma limited

Ann: Half Yearly Report and Accounts, page-5

  1. 4,149 Posts.
    "The other three therapeutic indications (hepatitis B, AMD and OPMD) are being progressed through their respective stages in the development pathway.
    Benitec anticipates completing in vivo preclinical proof of concept studies for all three indications by the end of 2016.
    The Company will require additional financing to conduct clinical trials with these product candidates."
    Throwing everything at shareholders today...who does this kind of sadistic work??​
 
watchlist Created with Sketch. Add BLT (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.